The inactivated influenza vaccine market size has grown strongly in recent years. It will grow from $7.14 billion in 2025 to $7.72 billion in 2026 at a compound annual growth rate (CAGR) of 8.2%. The growth in the historic period can be attributed to increasing seasonal influenza incidence, expansion of immunization programs, rising awareness of preventive healthcare, availability of egg-based vaccine production, growth of public health initiatives.
The inactivated influenza vaccine market size is expected to see strong growth in the next few years. It will grow to $10.55 billion in 2030 at a compound annual growth rate (CAGR) of 8.1%. The growth in the forecast period can be attributed to increasing focus on pandemic preparedness, rising investments in cell-based and recombinant vaccines, expansion of adult and elderly immunization coverage, growing government procurement of vaccines, increasing innovation in vaccine manufacturing technologies. Major trends in the forecast period include increasing adoption of quadrivalent influenza vaccines, rising focus on high-dose and adjuvanted vaccines, expansion of seasonal vaccination programs, growing emphasis on cold-chain optimization, enhanced focus on vaccine manufacturing scalability.
The growth of government vaccination programs is significantly boosting the inactivated influenza vaccine market. As public health awareness increases, governments are enhancing their immunization efforts, leading to greater demand for vaccines and more accessible immunization services. These programs play a critical role in providing free or subsidized inactivated influenza vaccines to high-risk groups, ensuring widespread vaccine coverage, and reducing the seasonal burden of influenza. For example, in December 2023, the UK’s National Health Service (NHS) introduced a new vaccination strategy aimed at improving immunization outreach, particularly to underserved and marginalized communities. This strategy is designed to expand vaccination accessibility and further promote public health, which in turn is expected to drive growth in the inactivated influenza vaccine market.
Leading companies in the inactivated influenza vaccine market are increasingly focusing on the development of quadrivalent vaccines. These vaccines are designed to protect against four distinct strains of the influenza virus, offering broader protection and improving vaccine efficacy. For example, in February 2025, Zydus Lifesciences, an India-based pharmaceutical company, launched VaxiFlu-4, a quadrivalent inactivated influenza vaccine that provides protection against four strains of the flu virus. By covering both influenza A and B strains, this vaccine reduces the risk of vaccine mismatch and enhances protection against seasonal flu outbreaks, while also tailoring immune responses to regional epidemiological trends.
In July 2024, GSK plc, a UK-based pharmaceutical company, expanded its capabilities in mRNA vaccine development by acquiring the full rights to develop, manufacture, and commercialize mRNA-based influenza and COVID-19 vaccines from CureVac N.V. for an undisclosed amount. This acquisition allows GSK to leverage CureVac’s advanced mRNA research to improve seasonal flu vaccines and boost pandemic preparedness strategies. CureVac, a Germany-based biotechnology company, specializes in mRNA-based therapeutics, including vaccines for influenza and cancer immunotherapy.
Major companies operating in the inactivated influenza vaccine market are Sanofi S.A., GlaxoSmithKline plc, CSL Limited, Viatris Inc., Zydus Lifesciences Limited, Sinovac Biotech Ltd., Bharat Biotech International Limited, Hualan Biological Bacterin Co. Ltd., Changchun Biological Products Co. Ltd., Dalian Aleph Biomedical Co. Ltd., Jiangsu GDK Biotechnology Co. Ltd., KM Biologics Co. Ltd., JoinHub Pharma, Seqirus (CSL Influenza Division), Serum Institute of India Pvt. Ltd., Biological E. Limited, Shenzhen Sanofi Pasteur Biologicals Co. Ltd., Beijing Tiantan Biological Products Co. Ltd., Wuhan Institute of Biological Products Co. Ltd., Lanzhou Institute of Biological Products Co. Ltd., Chengdu Institute of Biological Products Co. Ltd., Sinopharm CNBG, Takeda Pharmaceutical Company Limited, Pfizer.
North America was the largest region in the inactivated influenza vaccine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the inactivated influenza vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the inactivated influenza vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are influencing the inactivated influenza vaccine market by increasing costs of imported bioreactors, filtration systems, vials, syringes, and cold-chain equipment used across vaccine production and distribution. Pharmaceutical manufacturers in North America and Europe are most affected due to dependence on specialized imported inputs, while Asia-Pacific faces cost pressures on vaccine export logistics. These tariffs are increasing production costs and influencing vaccine pricing structures. At the same time, they are encouraging regional vaccine manufacturing expansion, local sourcing of packaging and delivery components, and greater investment in domestic vaccine supply capabilities to improve long-term availability.
The inactivated influenza vaccine market research report is one of a series of new reports that provides inactivated influenza vaccine market statistics, including inactivated influenza vaccine industry global market size, regional shares, competitors with a inactivated influenza vaccine market share, detailed inactivated influenza vaccine market segments, market trends and opportunities, and any further data you may need to thrive in the inactivated influenza vaccine industry. This inactivated influenza vaccine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Inactivated influenza vaccines are flu vaccines that contain viruses that have been killed or inactivated. These vaccines stimulate the immune system to produce antibodies against the influenza virus and are administered via injection to help prevent seasonal influenza infections.
The main types of vaccines in the inactivated influenza vaccine market include the trivalent inactivated influenza vaccine (TIIV) and the quadrivalent inactivated influenza vaccine (QIIV). The trivalent inactivated influenza vaccine contains three inactivated virus strains two influenza A strains and one influenza B strain to provide protection against seasonal influenza. These vaccines are used across various age groups, including children, adolescents, adults, and the elderly, and are distributed through hospital pharmacies, retail pharmacies, online pharmacies, and public health clinics. End users include healthcare providers, individuals, government organizations, and pharmaceutical companies.
The inactivated influenza vaccine market consists of sales of adjuvanted inactivated influenza vaccines, preservative-free inactivated influenza vaccines, cell-based inactivated influenza vaccines, egg-based inactivated influenza vaccines, pediatric inactivated influenza vaccines, high-dose inactivated influenza vaccines for older adults, prefilled syringe vaccines, and multidose vial vaccines. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The inactivated influenza vaccine market size is expected to see strong growth in the next few years. It will grow to $10.55 billion in 2030 at a compound annual growth rate (CAGR) of 8.1%. The growth in the forecast period can be attributed to increasing focus on pandemic preparedness, rising investments in cell-based and recombinant vaccines, expansion of adult and elderly immunization coverage, growing government procurement of vaccines, increasing innovation in vaccine manufacturing technologies. Major trends in the forecast period include increasing adoption of quadrivalent influenza vaccines, rising focus on high-dose and adjuvanted vaccines, expansion of seasonal vaccination programs, growing emphasis on cold-chain optimization, enhanced focus on vaccine manufacturing scalability.
The growth of government vaccination programs is significantly boosting the inactivated influenza vaccine market. As public health awareness increases, governments are enhancing their immunization efforts, leading to greater demand for vaccines and more accessible immunization services. These programs play a critical role in providing free or subsidized inactivated influenza vaccines to high-risk groups, ensuring widespread vaccine coverage, and reducing the seasonal burden of influenza. For example, in December 2023, the UK’s National Health Service (NHS) introduced a new vaccination strategy aimed at improving immunization outreach, particularly to underserved and marginalized communities. This strategy is designed to expand vaccination accessibility and further promote public health, which in turn is expected to drive growth in the inactivated influenza vaccine market.
Leading companies in the inactivated influenza vaccine market are increasingly focusing on the development of quadrivalent vaccines. These vaccines are designed to protect against four distinct strains of the influenza virus, offering broader protection and improving vaccine efficacy. For example, in February 2025, Zydus Lifesciences, an India-based pharmaceutical company, launched VaxiFlu-4, a quadrivalent inactivated influenza vaccine that provides protection against four strains of the flu virus. By covering both influenza A and B strains, this vaccine reduces the risk of vaccine mismatch and enhances protection against seasonal flu outbreaks, while also tailoring immune responses to regional epidemiological trends.
In July 2024, GSK plc, a UK-based pharmaceutical company, expanded its capabilities in mRNA vaccine development by acquiring the full rights to develop, manufacture, and commercialize mRNA-based influenza and COVID-19 vaccines from CureVac N.V. for an undisclosed amount. This acquisition allows GSK to leverage CureVac’s advanced mRNA research to improve seasonal flu vaccines and boost pandemic preparedness strategies. CureVac, a Germany-based biotechnology company, specializes in mRNA-based therapeutics, including vaccines for influenza and cancer immunotherapy.
Major companies operating in the inactivated influenza vaccine market are Sanofi S.A., GlaxoSmithKline plc, CSL Limited, Viatris Inc., Zydus Lifesciences Limited, Sinovac Biotech Ltd., Bharat Biotech International Limited, Hualan Biological Bacterin Co. Ltd., Changchun Biological Products Co. Ltd., Dalian Aleph Biomedical Co. Ltd., Jiangsu GDK Biotechnology Co. Ltd., KM Biologics Co. Ltd., JoinHub Pharma, Seqirus (CSL Influenza Division), Serum Institute of India Pvt. Ltd., Biological E. Limited, Shenzhen Sanofi Pasteur Biologicals Co. Ltd., Beijing Tiantan Biological Products Co. Ltd., Wuhan Institute of Biological Products Co. Ltd., Lanzhou Institute of Biological Products Co. Ltd., Chengdu Institute of Biological Products Co. Ltd., Sinopharm CNBG, Takeda Pharmaceutical Company Limited, Pfizer.
North America was the largest region in the inactivated influenza vaccine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the inactivated influenza vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the inactivated influenza vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are influencing the inactivated influenza vaccine market by increasing costs of imported bioreactors, filtration systems, vials, syringes, and cold-chain equipment used across vaccine production and distribution. Pharmaceutical manufacturers in North America and Europe are most affected due to dependence on specialized imported inputs, while Asia-Pacific faces cost pressures on vaccine export logistics. These tariffs are increasing production costs and influencing vaccine pricing structures. At the same time, they are encouraging regional vaccine manufacturing expansion, local sourcing of packaging and delivery components, and greater investment in domestic vaccine supply capabilities to improve long-term availability.
The inactivated influenza vaccine market research report is one of a series of new reports that provides inactivated influenza vaccine market statistics, including inactivated influenza vaccine industry global market size, regional shares, competitors with a inactivated influenza vaccine market share, detailed inactivated influenza vaccine market segments, market trends and opportunities, and any further data you may need to thrive in the inactivated influenza vaccine industry. This inactivated influenza vaccine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Inactivated influenza vaccines are flu vaccines that contain viruses that have been killed or inactivated. These vaccines stimulate the immune system to produce antibodies against the influenza virus and are administered via injection to help prevent seasonal influenza infections.
The main types of vaccines in the inactivated influenza vaccine market include the trivalent inactivated influenza vaccine (TIIV) and the quadrivalent inactivated influenza vaccine (QIIV). The trivalent inactivated influenza vaccine contains three inactivated virus strains two influenza A strains and one influenza B strain to provide protection against seasonal influenza. These vaccines are used across various age groups, including children, adolescents, adults, and the elderly, and are distributed through hospital pharmacies, retail pharmacies, online pharmacies, and public health clinics. End users include healthcare providers, individuals, government organizations, and pharmaceutical companies.
The inactivated influenza vaccine market consists of sales of adjuvanted inactivated influenza vaccines, preservative-free inactivated influenza vaccines, cell-based inactivated influenza vaccines, egg-based inactivated influenza vaccines, pediatric inactivated influenza vaccines, high-dose inactivated influenza vaccines for older adults, prefilled syringe vaccines, and multidose vial vaccines. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Inactivated Influenza Vaccine Market Characteristics
3. Inactivated Influenza Vaccine Market Supply Chain Analysis
4. Global Inactivated Influenza Vaccine Market Trends and Strategies
5. Inactivated Influenza Vaccine Market Analysis of End Use Industries
7. Global Inactivated Influenza Vaccine Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Inactivated Influenza Vaccine Total Addressable Market (TAM) Analysis for the Market
9. Inactivated Influenza Vaccine Market Segmentation
10. Inactivated Influenza Vaccine Market Regional and Country Analysis
11. Asia-Pacific Inactivated Influenza Vaccine Market
12. China Inactivated Influenza Vaccine Market
13. India Inactivated Influenza Vaccine Market
14. Japan Inactivated Influenza Vaccine Market
15. Australia Inactivated Influenza Vaccine Market
16. Indonesia Inactivated Influenza Vaccine Market
17. South Korea Inactivated Influenza Vaccine Market
18. Taiwan Inactivated Influenza Vaccine Market
19. South East Asia Inactivated Influenza Vaccine Market
20. Western Europe Inactivated Influenza Vaccine Market
21. UK Inactivated Influenza Vaccine Market
22. Germany Inactivated Influenza Vaccine Market
23. France Inactivated Influenza Vaccine Market
24. Italy Inactivated Influenza Vaccine Market
25. Spain Inactivated Influenza Vaccine Market
26. Eastern Europe Inactivated Influenza Vaccine Market
27. Russia Inactivated Influenza Vaccine Market
28. North America Inactivated Influenza Vaccine Market
29. USA Inactivated Influenza Vaccine Market
30. Canada Inactivated Influenza Vaccine Market
31. South America Inactivated Influenza Vaccine Market
32. Brazil Inactivated Influenza Vaccine Market
33. Middle East Inactivated Influenza Vaccine Market
34. Africa Inactivated Influenza Vaccine Market
36. Inactivated Influenza Vaccine Market Competitive Landscape and Company Profiles
37. Inactivated Influenza Vaccine Market Other Major and Innovative Companies
40. Inactivated Influenza Vaccine Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Inactivated Influenza Vaccine Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses inactivated influenza vaccine market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for inactivated influenza vaccine? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The inactivated influenza vaccine market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Type Of Vaccine: Trivalent Inactivated Influenza Vaccine (TIIV); Quadrivalent Inactivated Influenza Vaccine (QIIV)2) By Application: Children; Adolescence; Adults; Elderly
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Public Health Clinics
4) By End-User: Healthcare Providers; Individuals; Government Organizations; Pharmaceutical Companies
Subsegments:
1) Trivalent Inactivated Influenza Vaccine (TIIV): Egg-based Trivalent Inactivated Influenza Vaccine; Cell-based Trivalent Inactivated Influenza Vaccine; Adjuvanted Trivalent Inactivated Influenza Vaccine; High-dose Trivalent Inactivated Influenza Vaccine2) Quadrivalent Inactivated Influenza Vaccine (QIIV): Egg-based Quadrivalent Inactivated Influenza Vaccine; Cell-based Quadrivalent Inactivated Influenza Vaccine; Adjuvanted Quadrivalent Inactivated Influenza Vaccine; Recombinant Quadrivalent Inactivated Influenza Vaccine; Pediatric Quadrivalent Inactivated Influenza Vaccine
Companies Mentioned: Sanofi S.A.; GlaxoSmithKline plc; CSL Limited; Viatris Inc.; Zydus Lifesciences Limited; Sinovac Biotech Ltd.; Bharat Biotech International Limited; Hualan Biological Bacterin Co. Ltd.; Changchun Biological Products Co. Ltd.; Dalian Aleph Biomedical Co. Ltd.; Jiangsu GDK Biotechnology Co. Ltd.; KM Biologics Co. Ltd.; JoinHub Pharma; Seqirus (CSL Influenza Division); Serum Institute of India Pvt. Ltd.; Biological E. Limited; Shenzhen Sanofi Pasteur Biologicals Co. Ltd.; Beijing Tiantan Biological Products Co. Ltd.; Wuhan Institute of Biological Products Co. Ltd.; Lanzhou Institute of Biological Products Co. Ltd.; Chengdu Institute of Biological Products Co. Ltd.; Sinopharm CNBG; Takeda Pharmaceutical Company Limited; Pfizer
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Inactivated Influenza Vaccine market report include:- Sanofi S.A.
- GlaxoSmithKline plc
- CSL Limited
- Viatris Inc.
- Zydus Lifesciences Limited
- Sinovac Biotech Ltd.
- Bharat Biotech International Limited
- Hualan Biological Bacterin Co. Ltd.
- Changchun Biological Products Co. Ltd.
- Dalian Aleph Biomedical Co. Ltd.
- Jiangsu GDK Biotechnology Co. Ltd.
- KM Biologics Co. Ltd.
- JoinHub Pharma
- Seqirus (CSL Influenza Division)
- Serum Institute of India Pvt. Ltd.
- Biological E. Limited
- Shenzhen Sanofi Pasteur Biologicals Co. Ltd.
- Beijing Tiantan Biological Products Co. Ltd.
- Wuhan Institute of Biological Products Co. Ltd.
- Lanzhou Institute of Biological Products Co. Ltd.
- Chengdu Institute of Biological Products Co. Ltd.
- Sinopharm CNBG
- Takeda Pharmaceutical Company Limited
- Pfizer
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 7.72 Billion |
| Forecasted Market Value ( USD | $ 10.55 Billion |
| Compound Annual Growth Rate | 8.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 25 |
